-+ 0.00%
-+ 0.00%
-+ 0.00%

The Surgical Science Sweden AB (publ) (STO:SUS) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Simply Wall St·11/15/2026 06:55:48
Listen to the news

Surgical Science Sweden AB (publ) (STO:SUS) shareholders are probably feeling a little disappointed, since its shares fell 8.4% to kr56.45 in the week after its latest quarterly results. Surgical Science Sweden reported kr260m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of kr0.67 beat expectations, being 3.0% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

earnings-and-revenue-growth
OM:SUS Earnings and Revenue Growth November 15th 2026

Taking into account the latest results, the consensus forecast from Surgical Science Sweden's five analysts is for revenues of kr1.14b in 2027. This reflects a solid 11% improvement in revenue compared to the last 12 months. Per-share earnings are expected to surge 42% to kr2.97. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr1.14b and earnings per share (EPS) of kr3.03 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

See our latest analysis for Surgical Science Sweden

There were no changes to revenue or earnings estimates or the price target of kr72.20, suggesting that the company has met expectations in its recent result. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Surgical Science Sweden at kr85.00 per share, while the most bearish prices it at kr60.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Surgical Science Sweden shareholders.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Surgical Science Sweden's past performance and to peers in the same industry. We would highlight that Surgical Science Sweden's revenue growth is expected to slow, with the forecast 9.1% annualised growth rate until the end of 2027 being well below the historical 14% p.a. growth over the last five years. Compare this to the 48 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 9.6% per year. So it's pretty clear that, while Surgical Science Sweden's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Surgical Science Sweden going out to 2028, and you can see them free on our platform here..

Before you take the next step you should know about the 1 warning sign for Surgical Science Sweden that we have uncovered.